News & Events zu Onconetix Inc (ONCO)ONCOOnconetix Inc

Realbotix Increases Loan by $500,000 to Support Merger

Realbotix announces that its wholly owned subsidiary, Realbotix, has agreed to an additional advance of $500,000 in connection with the loan agreement entered into with Onconetix on September 14 in connection with the proposed merger transaction involving Realbotix and Onconetix previously announced on February 12. The additional draw increases the aggregate amount advanced under the facility from $2,500,000 to $3,000,000, out of the total $5,000,000 available under the agreement. The facility is an unsecured promissory note from Onconetix, as lender, to Realbotix, as borrower, and is guaranteed by Realbotix Corp. The note is non-interest-bearing and, upon closing of the merger, the note and all obligations under the loan documents will be automatically cancelled and discharged in full, without payment by Realbotix or Realbotix Corp. If the merger agreement is terminated, interest will accrue on the outstanding principal amount at 12% per annum from the date of termination.

Realbotix Enters $2.5M Unsecured Loan Agreement with Onconetix

Realbotix Corp. (XBOTF) entered into a loan agreement with Onconetix (ONCO) for an unsecured bridge loan facility in connection with the proposed merger transaction involving Realbotix LLC and Onconetix previously announced on February 12. The bridge loan provides transaction-aligned working capital to Realbotix LLC while the parties advance the merger. Onconetix is the lender, Realbotix LLC is the borrower, and Realbotix Corp. provides a guarantee of payment under the note. The facility consists of an unsecured promissory note with an initial draw of $2,500,000 and additional draws available up to an aggregate amount of $5,000,000. The note is non-interest bearing. At closing of the merger, the note and all obligations under the loan documents will be automatically cancelled and discharged in full, without payment by Realbotix LLC or Realbotix Corp. If the merger agreement is terminated, interest accrues on the outstanding principal amount at 12% per annum from the date of termination.

Company Not Selling Up to 100M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 100M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.